Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0I7GE
|
||||
| Former ID |
DNC004772
|
||||
| Drug Name |
ALPHA-NAPHTHOFLAVONE
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Discovery agent | Investigative | [527386] | ||
| Formula |
C19H12O2
|
||||
| Canonical SMILES |
C1=CC=C(C=C1)C2=CC(=O)C3=C(O2)C4=CC=CC=C4C=C3
|
||||
| InChI |
1S/C19H12O2/c20-17-12-18(14-7-2-1-3-8-14)21-19-15-9-5-4-6-13(15)10-11-16(17)19/h1-12H
|
||||
| InChIKey |
VFMMPHCGEFXGIP-UHFFFAOYSA-N
|
||||
| PubChem Compound ID | |||||
| Target and Pathway | |||||
| Target(s) | Cytochrome P450 19 | Target Info | Inhibitor | [530867] | |
| DNA-dependent protein kinase catalytic subunit | Target Info | Inhibitor | [527386] | ||
| NetPath Pathway | FSH Signaling PathwayNetPath_13:IL1 Signaling Pathway | ||||
| PANTHER Pathway | Androgen/estrogene/progesterone biosynthesis | ||||
| PathWhiz Pathway | Androgen and Estrogen Metabolism | ||||
| WikiPathways | Metapathway biotransformation | ||||
| Tryptophan metabolism | |||||
| Oxidation by Cytochrome P450 | |||||
| Ovarian Infertility Genes | |||||
| Metabolism of steroid hormones and vitamin D | |||||
| FSH signaling pathway | |||||
| Integrated Breast Cancer Pathway | |||||
| Phase 1 - Functionalization of compoundsWP707:DNA Damage Response | |||||
| Non-homologous end joining | |||||
| FAS pathway and Stress induction of HSP regulation | |||||
| Cytosolic sensors of pathogen-associated DNA | |||||
| Retinoblastoma (RB) in Cancer | |||||
| Prostate Cancer | |||||
| Double-Strand Break Repair | |||||
| Cell Cycle | |||||
| miRNA Regulation of DNA Damage Response | |||||
| References | |||||
| Ref 527386 | J Med Chem. 2005 Jan 27;48(2):569-85.Selective benzopyranone and pyrimido[2,1-a]isoquinolin-4-one inhibitors of DNA-dependent protein kinase: synthesis, structure-activity studies, and radiosensitization of a human tumor cell line in vitro. | ||||
| Ref 530867 | Bioorg Med Chem Lett. 2010 May 15;20(10):3050-64. Epub 2010 Apr 8.Pharmacophore modeling strategies for the development of novel nonsteroidal inhibitors of human aromatase (CYP19). | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Tang and Dr. Zhang.